Evaluation Study
Journal Article
Add like
Add dislike
Add to saved papers

A critical appraisal on pure neuritic leprosy from India after achieving WHO global target of leprosy elimination.

Leprosy Review 2016 December
BACKGROUND: Clinical data on pure-neuritic leprosy (PNL) is limited.

OBJECTIVE: To study the clinical and epidemiological features of PNL in the leprosy post-elimination era.

METHODS: This was a retrospective analysis of the clinic records of leprosy patients from January 2006 to June 2013. Data regarding age, sex, disease duration, presenting complaints, nerves affected, complications and treatment received were extracted from PNL cases.

RESULTS: Among 906 registered leprosy cases, 48 (5·3%) were found to have PNL. The mean age was 36·9 ± 16·2 years and predominantly males were affected (85·4%). The mean delay between onset of symptoms and diagnosis was 2·1 ± 2·2 years. Multiple nerves were affected in 36 patients (75%) and 12 (25%) had only one nerve involved. Visible deformities at presentation were noted in 32 (66·7%) patients. Forty patients (83·3%) were treated with multi drug therapy-multibacillary (MDTMB) regimen and three (6·25%) were treated with MDT-paucibacillary regimen. Twenty-one patients (43·8%) were considered positive responders to treatment. There was no correlation between the duration of NFI and treatment outcome.

CONCLUSION: PNL continues to occur in the post-elimination era. Grade 2 deformities are common in PNL compared to other leprosy patients because of delayed diagnosis and treatment. Distinct diagnosis and treatment guidelines and sensitisation of health care workers and physicians to the occurrence of PNL is the need of the day.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app